At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 200 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
To Observe and Evaluate the Efficacy and Safety of Inaticabtagene Autoleucel Injection in the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia in Adults in the Real World
In Brief
An observational study for B-cell Acute Lymphoblastic Leukemia. Currently recruiting, targeting 200 participants across 10 sites.
Detailed Summary
This clinical trial is a non-interventional, observational, multicenter, post-marketing real-world study to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in Chinese adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsB-cell Acute Lymphoblastic Leukemia
CountriesChina
Collaborators--
Timeline
N/ARecruiting
20252026202720282029
Enrollment StartJun 2024
First PostedJun 2024
Primary CompletionJun 2026
TodayJul 2026
Study CompletionJun 2029
First PostedJun 10, 2024
Enrollment StartJun 5, 2024
Primary CompletionJun 5, 2026
Study CompletionJun 5, 2029
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 2.1 years ago